CYBERDYNE Inc. (CYBQY)
OTCMKTS · Delayed Price · Currency is USD
1.070
-0.120 (-10.08%)
At close: Dec 12, 2025
CYBERDYNE Revenue
CYBERDYNE had revenue of 963.00M JPY in the quarter ending September 30, 2025, a decrease of -2.53%. This brings the company's revenue in the last twelve months to 4.20B, down -4.30% year-over-year. In the fiscal year ending March 31, 2025, CYBERDYNE had annual revenue of 4.38B with 0.69% growth.
Revenue (ttm)
4.20B JPY
Revenue Growth
-4.30%
P/S Ratio
9.43
Revenue / Employee
19.92M JPY
Employees
211
Market Cap
267.88M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.38B | 30.00M | 0.69% |
| Mar 31, 2024 | 4.35B | 1.07B | 32.38% |
| Mar 31, 2023 | 3.29B | 1.14B | 52.98% |
| Mar 31, 2022 | 2.15B | 275.00M | 14.67% |
| Mar 31, 2021 | 1.88B | 83.00M | 4.63% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |